4C supply deal has nothing to do with the deal that was done with Lemaitre, The deal with 4C was to supply tissue not products (ex Cardiocel) in 3 years time manufacturing will be retained minus the products that were sold to Lemaitre, so company will be making the TAVR and any new products that they come up with.
I believe the 3 years limit for Admedus to manufacture for Lemaitre was set by Admedus, this way they can free up the manufacturing capacity to make the TAVR and ??????
DYOR
4C supply deal has nothing to do with the deal that was done...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |